We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Understanding EGFR Signaling Networks May Lead to New Cancer Treatments

By LabMedica International staff writers
Posted on 20 Jun 2012
Cancer researchers have shown that a combination of drugs already approved by the [US] Food and Drug Administration (FDA) could block the oncogenic activity of EGFR (epidermal growth factor receptor) and restore drug sensitivity in advanced cases of metastatic lung adenocarcinoma.

EGFR activation is both a key molecular driver of cancer progression and the target of a broad class of molecular agents designed to treat advanced forms of the disease. More...
Nevertheless, drug resistance develops through several mechanisms, including activation of AKT signaling. AKT, also known as protein kinase B (PKB), is a serine/threonine-specific protein kinase that plays a key role in multiple cellular processes such as glucose metabolism, apoptosis, cell proliferation, transcription, and cell migration.

Investigators at Case Western Reserve University (Cleveland, OH, USA) and colleagues at Mount Sinai School of Medicine (New York, NY, USA) characterized the downstream mediators of EGFR signaling in order to develop new classes of targeted molecular therapies to treat resistant forms of cancer.

They reported in the June 1, 2012, online edition of the Journal of Clinical Investigation that they had identified a transcriptional network involving the tumor suppressor proteins Krüppel-like factor 6 (KLF6) and forkhead box O1 (FOXO1). KLF6 and FOXO1 are tumor suppressor genes that are turned off in actively growing cancer cells.

Working with both cell culture and xenograft models of lung adenocarcinoma, the investigators showed that the use of the FDA-approved drug trifluoperazine hydrochloride (a medication used to treat schizophrenia), which had been shown to inhibit FOXO1 nuclear export, restored sensitivity to AKT-driven erlotinib (a targeted cancer drug) resistance through modulation of the KLF6/FOXO1 signaling cascade.

“Because of the financial constraints and length of time it takes to bring new drugs through clinical trials, scientists are moving toward using existing drugs in new ways so that the process of translating the discoveries of today into the treatments of tomorrow can be accelerated,” said senior author Dr. Goutham Narla, assistant professor of medicine at Case Western Reserve University.

Results of this study highlight the central importance of defining key signaling networks in cancer and the potential use of this information to identify clinically relevant modulators of treatment response.

Related Links:

Case Western Reserve University
Mount Sinai School of Medicine



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.